Head-to-head · WeighScore
Invigor Medical vs VevaRX
The verdict
Invigor Medical takes it — 86.1/100 to 54.7/100.
Invigor Medical grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. An established pharmacy operator with steady mid-market pricing and a broad catalog.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Invigor Medical | VevaRX |
|---|---|---|
| WeighScore | 86.1/100 | 54.7/100 |
| Grade | B | C |
| Site position | #10 | #503 |
| Semaglutide | $199/mo | $189/mo (the same page also prints $167 a month and $467 for three months) |
| Tirzepatide | $339/mo | $467 per three months, auto-renewing (about $155.67 a month; no monthly option is offered) |
| Coverage | Not disclosed | 36 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #10 · B
Strengths
- Mid-market pricing on both molecules
- Long-running operator
Where it loses points
- No explicit states list
- Compounded only
Site position #503 · C
Strengths
- Publishes an exact 36-state list by name rather than a nationwide claim it then hedges
- States what the three-month figure covers — medication, supplies and the provider visit — and includes free two- to three-day shipping
- Unlimited physician access and a 24/7 care team are described as inside the program price
- Prices its peptide products openly beside the GLP-1 lines
Where it loses points
- Tirzepatide has no monthly option: it is sold as $467 for three months on a quarterly auto-renewal with a three-month minimum
- The tirzepatide page's own arithmetic is wrong — it calls $467 equivalent to $149 a month when the figure is $155.67, which the semaglutide page states correctly
- The semaglutide page carries four prices, two of which belong to tirzepatide
- Follow-up consultations are priced separately at $299 and $399, which the program pages do not mention
- NAD+ is priced three different ways on one page, at $399, $447 and $267
- Another company's domain appears in VevaRX's own Terms, in the transaction currency clause
- The contact page FAQ is a different product's copy and gives dosing instructions for a powdered drink under the question of how to take semaglutide or tirzepatide
- Two opposite return policies are live, and no pharmacy, compounding class, clinician or medical group is named anywhere
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). CoreAge Rx advertises flat dose pricing for compounded injections, with no membership fee; its consultation-fee and refund deadlines deserve a close read before paying.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.